Rhythm expects to dose first Phase III bivamelagon HO patients in January as it commits to $350M royalty buy-down

Nigeria South Africa Ghana Senegal Uganda Kenya Morocco Egypt Zimbabwe Tanzania Algeria Ethiopia Ivory Coast Sudan Libya Somalia Tunisia Zambia Mozambique DR Congo Angola

India Malaysia South Korea China Israel Iran Japan United Arab Emirates Philippines Saudi Arabia Cambodia Turkey Singapore Pakistan Indonesia Thailand North Korea Vietnam Yemen Palestine Nepal Taiwan Kazakhstan Bangladesh Iraq Lebanon Syria Qatar Sri Lanka Afghanistan Jordan Uzbekistan Kuwait Laos

United Kingdom Germany Russia Spain France Italy Ukraine Portugal Ireland Austria Finland Romania Switzerland Netherlands Czech Republic Poland Greece Hungary Sweden Norway Denmark Belgium Serbia Croatia Bulgaria Georgia Slovakia Belarus Slovenia Iceland

United States Mexico Canada Dominican Republic Costa Rica Guatemala Puerto Rico Honduras Jamaica Cuba Panama Belize Nicaragua El Salvador Haiti Bahamas Trinidad and Tobago Barbados

Brazil Peru Colombia Argentina Ecuador Venezuela Bolivia Uruguay Chile Paraguay

Australia New Zealand Papua New Guinea Fiji